17
Participants
Start Date
April 18, 2023
Primary Completion Date
May 11, 2024
Study Completion Date
March 11, 2025
ECCO2R
ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.
Hôpital Nord, Marseille
CHU Besançon, Besançon
Hôpital d'Instruction des Armées Robert Picqué, Villenave-d'Ornon
CHU Lapeyronie, Montpellier
CHU Pontchaillou, Rennes
CHRU Bretonneau, Tours
CHR Orléans, Orléans
CHU Angers, Angers
Nouvel Hôpital Civil Strasbourg, Strasbourg
Hôpital de la Croix-Rousse, Lyon
CH Le Mans, Le Mans
Hôpital La Pitié Salpêtrière, AP-HP, Paris
Hôpital Cochin - APHP, Paris
Hôpital européen Georges Pompidou - APHP, Paris
Hôpital Tenon, Paris
CHU Rouen, Rouen
CHD de Vendée, La Roche-sur-Yon
CHU la Milétrie, Poitiers
Hôpital Avicennes, AP-HP, Bobigny
Centre Hospitalier de Saint Denis, Saint-Denis
Ministry of Health, France
OTHER_GOV
Xenios AG
INDUSTRY
Assistance Publique - Hôpitaux de Paris
OTHER